ClinicalTrials.gg
RecruitingNCT07944196GUMIDICUpdated Nov 18, 2026

Gut Microbiome Diversity in Adults With Inflammatory and Immune-Mediated Skin Diseases

An observational study in Atopic Dermatitis, Psoriasis and Hidradenitis Suppurativa (HS), sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Observational

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
694
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 83 studies in Dermatitis, Atopic with a site in Italy — 15 open to participants now, 27 under way, 9 of them phase 3. Dermatitis, Atopic · Italy.

Planned enrollment
8th of 14
694 · median 784
Started
2026
with 3 others
Observational
14 of 83
7 open now
Primary completion
2028-07
later than 17 of 26 live
Registered
83rd of 83
by date

Among the 83 studies in Dermatitis, Atopic with a site in Italy, this one is the 8th largest by planned enrollment of the 14 observational ones that give a count, is one of 4 that started in 2026, is one of 14 observational ones, reaches primary completion later than 17 of the 26 other live ones, and was the 83rd registered.

Dermatitis, Atopic

1,595 studies on the registry are indexed under Dermatitis, Atopic; 288 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

15 of the 83 studies in Dermatitis, Atopic with a site in Italy are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Dermatitis, Atopic with a site in Italy, or all of them as a file.
02

Study summary

This study will examine whether the gut bacteria of adults with inflammatory or immune-mediated skin diseases differ from those of healthy adults. It will include people with atopic dermatitis, psoriasis, hidradenitis suppurativa, vitiligo, alopecia areata, acne, pemphigus, or bullous pemphigoid, as well as healthy controls.

Participants will provide a stool sample and complete a short food diary. The study team will analyze the bacteria in the samples and compare the results between the disease groups and healthy controls. Participants with a skin disease will be asked to provide a second stool sample and complete follow-up assessments about six months later; healthy controls will provide one sample. The study will also examine whether changes in gut bacteria are related to skin disease severity, diet, and other collected health information.

03

Conditions studied

  • Atopic Dermatitis
  • Psoriasis
  • Hidradenitis Suppurativa (HS)
  • Vitiligo - Macular Depigmentation
  • Alopecia Areata
  • Acne
  • Pemphigus Vulgaris (PV)
  • Bullous Pemphigoid
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adults aged 18 years or older with one of eight specialist-confirmed inflammatory or immune-mediated skin diseases, plus healthy adult controls without those diseases. Participants are recruited through the Dermatology service at Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan, Italy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • Able and willing to provide .
  • For patient groups: specialist-confirmed diagnosis of atopic dermatitis, psoriasis, hidradenitis suppurativa, vitiligo, alopecia areata, acne, pemphigus, or bullous pemphigoid.
  • For healthy controls: no diagnosis of the skin diseases studied.

Exclusion criteria

Exclusion Criteria:

  • Unable to provide or complete the study procedures.
  • Systemic antibiotic treatment within 8 weeks before recruitment or during follow-up.
  • Previous intestinal surgery.
  • Inflammatory bowel disease, constipation, or diarrhea.
  • Long-term alcohol use.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
694 participants (estimated)
Patient registry
No

Groups and cohorts

  • Atopic Dermatitis

    Adults aged 18 years or older with dermatologist-confirmed atopic dermatitis. Participants provide a stool sample and complete study assessments at baseline and about six months later.

  • Psoriasis

    Adults aged 18 years or older with dermatologist-confirmed psoriasis. Participants provide a stool sample and complete study assessments at baseline and about six months later.

  • Hidradenitis Suppurativa

    Adults aged 18 years or older with dermatologist-confirmed hidradenitis suppurativa. Participants provide a stool sample and complete study assessments at baseline and about six months later.

  • Vitiligo

    Adults aged 18 years or older with dermatologist-confirmed vitiligo. Participants provide a stool sample and complete study assessments at baseline and about six months later.

  • Acne

    Adults aged 18 years or older with dermatologist-confirmed acne. Participants provide a stool sample and complete study assessments at baseline and about six months later.

  • Pemphigus

    Adults aged 18 years or older with dermatologist-confirmed pemphigus. Participants provide a stool sample and complete study assessments at baseline and about six months later.

  • Bullous Pemphigoid

    Adults aged 18 years or older with dermatologist-confirmed bullous pemphigoid. Participants provide a stool sample and complete study assessments at baseline and about six months later.

  • Healthy Controls

    Adults aged 18 years or older who do not have the skin diseases studied. Participants provide one stool sample and complete study assessments at baseline.

  • Alopecia Areata

    dults aged 18 years or older with dermatologist-confirmed alopecia areata. Participants provide a stool sample and complete study assessments at baseline and about six months later.

06

What researchers measure

Primary outcomes

  1. Relative abundance of Bifidobacteriaceae in stool

    Compare the relative abundance of the bacterial family Bifidobacteriaceae in stool between the combined group of adults with the eight skin diseases studied and healthy controls. Relative abundance is the number of sequences assigned to Bifidobacteriaceae divided by the total number of bacterial sequences.

    Time frame: Baseline (T1)

Secondary outcomes

  1. Relative abundance of Enterobacteriaceae in stool in the combined patient group

    Compare the relative abundance of Enterobacteriaceae in stool between the combined group of adults with the eight skin diseases studied and healthy controls.

    Time frame: Baseline (T1)

  2. Relative abundance of Bifidobacteriaceae by skin-disease group

    Compare stool Bifidobacteriaceae relative abundance between each disease group-atopic dermatitis, psoriasis, hidradenitis suppurativa, vitiligo, alopecia areata, acne, pemphigus, and bullous pemphigoid-and healthy controls.

    Time frame: Baseline (T1)

  3. Relative abundance of Enterobacteriaceae by skin-disease group

    Compare stool Enterobacteriaceae relative abundance between each of the eight disease groups and healthy controls.

    Time frame: Baseline (T1)

  4. Change in stool Bifidobacteriaceae and Enterobacteriaceae over time

    Assess within-person changes in the relative abundance of Bifidobacteriaceae and Enterobacteriaceae between T1 and T2 in participants with skin disease.

    Time frame: Baseline (T1) to 6 months (T2)

  5. Associations between gut bacteria and disease-related measures

    Explore associations between Bifidobacteriaceae and Enterobacteriaceae relative abundance and disease activity scores, psychological impact scores, available routine laboratory markers, dietary intake, and anthropometric measures, as specified in the protocol.

    Time frame: Baseline (T1) and 6 months (T2)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jul 2028, 27 months after the start.

Of 97 non-industry observational studies under Dermatitis, Atopic, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 19. This study's planned 27 months is below that.

Counting every sponsor, half of 171 studies reached it within 35 months; a quarter within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 18, 2026
StartActual
Apr 11, 2026
Primary completionEst.
Jul 31, 2028
CompletionEst.
Jan 31, 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944196
Collaborators
University of Milan
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Apr 11, 2026
Primary completion
Jul 31, 2028 (estimated)
Completion
Jan 31, 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Gianluca Nazzaro, MD
Contact
gianluca.nazzaro@policlinico.mi.it
+39 0255035200

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion